Amenorrhea, Primary

Important
It is possible that the main title of the report Amenorrhea, Primaryis not the name you expected.

Synonyms

Absence of Menstruation, Primary
PA

Disorder Subdivisions

None

General Discussion

Amenorrhea is the absense of menstrual periods. The term "primary amenorrhea" is used if periods have never started in females aged 16 or older. It is a rare gynecological disorder. Regular menstruation usually begins (menarche) within two years of the onset of puberty. Absence of menses by age 16-18 constitutes Primary Amenorrhea.

Resources

National Adrenal Diseases Foundation
505 Northern Boulevard
Great Neck
NY
11021
USA
Tel: (516)487-4992
Fax: (516)829-5710
NADFmail@aol.com
http://www.medhelp.org/nadf

American Autoimmune Related Diseases Association, Inc.
22100 Gratiot Avenue
Eastpointe
MI
48021-2227
Tel: (586)776-3900
Fax: (586)776-3903
800: (800)598-4668
aarda@aarda.org
http://www.aarda.org/

National Women's Health Network
514 10th Street NW
Suite 400
Washington
D.C.
20004
USA
Tel: (202)628-7814
Fax: (202)347-1168
nwhn@nwhn.org
http://www.womenshealthnetwork.org

AutoImmunity Community
Tel: (919) 552-9057
bandrews@autoimmunitycommunity.org
http://autoimmunitycommunity.org

For a Complete Report:

This is an abstract of a report from the National Organization for Rare Disorders, Inc. ® (NORD). A copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html

The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.

It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report

This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.

For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email orphan@rarediseases.org

Last Updated: 4/24/2008
Copyright 1986, 1989, 1993, 1994, 2000 National Organization for Rare Disorders, Inc.

WebMD Medical Reference from the National Organization of Rare Disorders

Last Updated: April 24, 2008

This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.

WebMD Editors' Picks

Depression: Learn about the Symptoms

As You Journey through Menopause, Vivelle-Dot Is By Your Side

VIVELLE-DOT (estradiol transdermal system) IS AVAILABLE BY PRESCRPTION ONLY.

INDICATION

Vivelle-Dot is used after menopause to: reduce moderate to severe hot flashes; treat moderate to severe dryness, itching and burning in or around the vagina; help reduce your chances of getting osteoporosis (thin weak bones); and treat certain conditions in which a young woman's ovaries do not produce enough estrogens naturally. Vivelle-Dot 0.025 mg/day is only used to prevent osteoporosis from menopause. If you use Vivelle-Dot only to treat your dryness, itching, and burning in and around your vagina or if you use Vivelle-Dot only to prevent osteoporosis from menopause, talk with your healthcare professional about whether a different treatment or medicine without estrogens might be better for you.

IMPORTANT SAFETY INFORMATION

Estrogens increase the chances of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are taking estrogens. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb).

Do not use estrogens with or without progestins to prevent heart disease, heart attacks, or strokes. Using estrogens with or without progestins may increase your chances of getting heart attacks, strokes, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of dementia (decline in memory and thinking skills).

Vivelle-Dot should not be used if you have unusual vaginal bleeding; currently have or have had certain cancers, including cancer of the breast or uterus; had a stroke or heart attack in the recent past (for example, in the past year); currently have or have had blood clots; currently have or have had liver problems; or think you may be, or know that you are, pregnant.

The most common side effects that may occur with Vivelle-Dot are headache, breast tenderness, and back pain.

You and your healthcare professional should talk regularly about whether you still need treatment with Vivelle-Dot.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information for Vivelle-Dot.

Prescribing Information